^
    Back
    Association details:
    Biomarker:HER-2 exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Drug:sunvozertinib (DZD9008) (EGFR inhibitor, HER2 inhibitor, BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    Published date:
    07/06/2022
    Excerpt:
    In addition, the preliminary antitumor activity of sunvo­zertinib was also observed in patients with EGFR sensitizing mutation, EGFR sensitizing/T790M double mutation, and HER2exon20ins (Supplementary Table S8).
    DOI:
    https://doi.org/10.1158/2159-8290.CD-21-1615